| Gamifant (emapalumab-lzsg) / SOBI |
| Completed | 3 | 35 | Europe, Canada, US | Emapalumab | Swedish Orphan Biovitrum | Primary Hemophagocytic Lymphohistiocytosis | 08/21 | 09/22 | | |
| Recruiting | 3 | 41 | Europe, Canada, Japan, US, RoW | Emapalumab, NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO) | Swedish Orphan Biovitrum | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | 09/24 | 09/25 | | |
NCT01818492 / 2012-003632-23: Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis |
|
|
| Completed | 2/3 | 45 | Europe, US | NI-0501 | Swedish Orphan Biovitrum, Seventh Framework Programme | Primary Haemophagocytic Lymphohistiocytosis | 01/19 | 01/19 | | |
2020-001167-93: A clinical trial investigating efficacy and safety of emapalumab and anakinra in patients with Coronavirus disease (COVID-19) Studio clinico per valutare l'efficacia e la sicurezza di emapalumab e anakinra in pazienti con COVID-19 |
|
|
| Not yet recruiting | 2/3 | 54 | Europe | Kineret, Emapalumab, [Kineret], [Emapalumab], Solution for injection, KINERET - "100 MG/0,67 ML SOLUZIONE INIETTABILE" USO SOTTOCUTANEO SIRINGA PRERIEMPITA 7 SIRINGHE PRERIEMPITE, Gamifant | SWEDISH ORPHAN BIOVITRUM AB (PUBL), Swedish Orphan Biovitrum AB (publ) | SARS-CoV-2 infection Infezione da SARS-CoV-2, Coronavirus disease (COVID-19) Malattia da Coronavirus (COVID-19), Diseases [C] - Virus Diseases [C02] | | | | |
NCT04324021: Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. |
|
|
| Terminated | 2/3 | 16 | Europe, US | Emapalumab, Gamifant, Anakinra, Kineret | Swedish Orphan Biovitrum | SARS-CoV-2 | 11/20 | 11/20 | | |
NCT02069899: A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody |
|
|
| Completed | 2/3 | 58 | Europe, US | Emapalumab, NI-0501 | Swedish Orphan Biovitrum, Seventh Framework Programme | Hemophagocytic Lymphohistiocytosis | 05/21 | 05/21 | | |
NCT03985423: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH |
|
|
| Terminated | 2/3 | 7 | US | Emapalumab-Lzsg, NI-0501 | Swedish Orphan Biovitrum, Light Chain Bioscience - Novimmune SA | Hemophagocytic Lymphohistiocytoses | 06/21 | 06/21 | | |
